Dogwood Therapeutics completes enrollment in Halneuron Phase 2b chemotherapy-induced neuropathic pain trial
DWTX•Phase 2b trial enrollment completed
Dogwood Therapeutics completed enrollment in its Halneuron Phase 2b trial in chemotherapy-induced neuropathic pain, reaching 239 patients.
Topline results have not been presented; the readout is expected in November 2026.
The study is designed to determine whether Halneuron reduces pain versus placebo in patients with neuropathic pain following prior chemotherapy.
Positive data could support further development of a non-opioid option in an indication with no FDA-approved treatments.
